肝胆相照论坛

标题: 处于不同表观遗传转录状态的乙型肝炎病毒 cccDNA 微染色体的 [打印本页]

作者: StephenW    时间: 2021-11-17 12:47     标题: 处于不同表观遗传转录状态的乙型肝炎病毒 cccDNA 微染色体的

处于不同表观遗传转录状态的乙型肝炎病毒 cccDNA 微染色体的损伤脆弱性不同
杨望1、李玉梦1、文静再1、孔瑛胡1、朱元飞1、邓强1 2、吴敏3、李亚明1、陈洁良1 2、袁征红1 2
隶属关系
隶属关系

    1
    复旦大学上海医学院基础医学院医学分子病毒学重点实验室(MOE/NHC/CAMS),上海,中国。
    2
    中国医学科学院慢性乙型肝炎病毒感染治疗研究组。
    3
    复旦大学上海公共卫生临床中心,上海,中国。

    PMID:34779008 DOI:10.1002/hep.32245

抽象的

背景和目的:乙型肝炎病毒 (HBV) 共价闭合环状 DNA (cccDNA) 是治愈慢性乙型肝炎的主要障碍。越来越多的证据表明表观遗传修饰调节 cccDNA 微染色体的转录活性。然而,目前尚不清楚 cccDNA 的表观遗传状态如何影响其稳定性。

方法和结果:通过使用HBV感染细胞模型、体外和体内重组cccDNA(rcccDNA)和HBVcircle模型,比较cccDNAs之间HBV cccDNA的减少率和APOBEC3A-和CRISPR/Cas9介导的cccDNA靶向的功效具有不同的转录活性。干扰素-α 处理和 HBx 缺失被用作 cccDNA 抑制的两种策略。进行染色质免疫沉淀和微球菌核酸酶测定以确定 cccDNA 的表观遗传模式。 HBV cccDNA 水平在非分裂肝细胞中保持稳定,但在细胞分裂过程中显着降低,并且在转录激活和转录抑制状态下的 cccDNA 之间降低率相似。引人注目的是,没有 HBx 表达的 HBV rcccDNA 在小鼠中表现出明显更长的持久性。低转录活性的 cccDNA 表现出表观遗传非活性模式,APOBEC3A 和工程化 CRISPR-Cas9 更难以访问。激活 cccDNA 的表观遗传调节因子增加了其对 APOBEC3A 的脆弱性。

结论:处于不同表观遗传转录状态的 HBV cccDNA 微染色体在细胞分裂过程中表现出相似的减少率,但它们对靶向核酸酶和抗病毒药物的可及性和易感性存在显着差异。 cccDNA 的表观遗传致敏使其更容易受到损伤,并可能有助于治愈 HBV。

关键词:CRISPR/Cas9; HBx; HDAC抑制剂;乙型肝炎病毒 (HBV);可访问性;共价闭合环状 DNA (cccDNA);表观遗传调控;干扰素(干扰素);稳定。

本文受版权保护。版权所有。
作者: StephenW    时间: 2021-11-17 12:48

Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage
Yang Wang  1 , Yumeng Li  1 , Wenjing Zai  1 , Kongying Hu  1 , Yuanfei Zhu  1 , Qiang Deng  1   2 , Min Wu  3 , Yaming Li  1 , Jieliang Chen  1   2 , Zhenghong Yuan  1   2
Affiliations
Affiliations

    1
    Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
    2
    Research Unit of Cure of Chronic Hepatitis B Virus Infection, Chinese Academy of Medical Sciences, China.
    3
    Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

    PMID: 34779008 DOI: 10.1002/hep.32245

Abstract

Background and aims: Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a major obstacle for a cure of chronic hepatitis B. Accumulating evidence suggests that epigenetic modifications regulate the transcriptional activity of cccDNA minichromosomes. However, it remains unclear how the epigenetic state of cccDNA affects its stability.

Approaches and results: By using HBV infection cell models, in vitro and in vivo recombinant cccDNA (rcccDNA) and the HBVcircle models, the reduction rate of HBV cccDNA and the efficacy of APOBEC3A- and CRISPR/Cas9-mediated cccDNA targeting were compared between cccDNAs with distinct transcriptional activities. Interferon-α treatment and HBx deletion were applied as two strategies for cccDNA repression. Chromatin immunoprecipitation and micrococcal nuclease assays were performed to determine the epigenetic pattern of cccDNA. The HBV cccDNA levels remained stable in non-dividing hepatocytes, however, they were significantly reduced during cell division, and the reduction rate was similar between cccDNAs in transcriptionally-active and transcriptionally-repressed states. Strikingly, HBV rcccDNA without HBx expression exhibited a significantly longer persistence in mice. The cccDNA in low transcriptional activity exhibited an epigenetic inactive pattern and was more difficult to access by APOBEC3A and engineered CRISPR-Cas9. The epigenetic regulator activating cccDNA increased its vulnerability to APOBEC3A.

Conclusions: HBV cccDNA minichromosomes in distinct epigenetic transcriptional states showed a similar reduction rate during cell division, but significantly differ in their accessibility and vulnerability to targeted nucleases and antiviral agents. Epigenetic sensitization of cccDNA makes it more susceptible to damage and may potentially contribute to an HBV cure.

Keywords: CRISPR/Cas9; HBx; HDAC inhibitor; Hepatitis B virus (HBV); accessibility; covalently closed circular DNA (cccDNA); epigenetic Regulation; interferon (IFN); stability.

This article is protected by copyright. All rights reserved.




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5